Abstract: The present invention relates to the dextro-rotatory enantiomer of Formula ##STR1## and its pharmaceutically acceptable salts with platelet aggregation inhibiting activity.The invention also relates to a process for the preparation of this compound starting from the racemate and the pharmaceutical compositions containing it.

Abstract: The present invention is concerned with compounds with the formula: ##STR1## in which: R.sub.1 represents a lower alkyl, a lower hydroxy alkyl or a benzyl group, a phenyl group or a 4-hydroxy phenyl group:R.sub.2 and R.sub.

Abstract: The present invention relates to novel derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro thieno [3,2-c] 5-pyridyl) phenyl acetic acid corresponding to the following general formula: ##STR1## their addition salts with pharmaceutically-acceptable inorganic or organic acids as well as isomers and their mixtures.The invention also relates to their process of preparation and to medicaments containing these compounds which are of therapeutic use as inhibitors of platelet- and thrombotic-aggregation.

Abstract: 2-Acyl-1,3,4,6,7,11b-hexahydro-2H-pyrazino-[2,1-a]-4-isoquinoleinones having anthelmintic activity of the formula ##STR1## are prepared from 4-acyl-2,6-dioxopierazines by reaction with a phenethyl halide, selective reduction of one of the oxo groups and cyclization, by the novel intermediates of formula ##STR2## in which Y represents O or H, OH.

Abstract: This invention relates to a new thieno-pyridinone derivative of the formula: ##STR1## and its pharmaceutically acceptable inorganic or organic acid addition salts.This invention relates also to a process for the preparation of said compound and to its therapeutic application as blood-platelet anti-aggregation agent and anti-thrombosis agent.

Abstract: This invention relates to a process for the preparation of antiinflammatory thieno [2,3-c]- and [3,2-c]pyridines having respectively the following formulae: ##STR1## in which R.sub.1 and R.sub.2, which may be the same or different, represent each a hydrogen atom or an alkyl group, and their pharmaceutically acceptable acid addition salts, comprising:(a) condensing a compound of the following formulae (VII) or (VIII), respectively, ##STR2## with a sulfonyl chloride having the formula ClSO.sub.2 R.sub.3, in which R.sub.3 is a lower alkyl radical or a phenyl radical optionally substituted with a halogen atom or a lower alkyl group, within a two-phase solvent system and in the presence of sodium carbonate;(b) oxidizing in a solvent medium the resulting alcohols having respectively the following formula (V) or (VI): ##STR3## (c) treating the resulting ketones, having the following formula (III) or (IV): ##STR4## with a basic agent having the formula RO.sup.- M.sup.

Abstract: This invention relates to compounds having the formula: ##STR1## in which: R.sup.1 represents hydrogen or a lower alkyl group; an aralkyl group optionally substituted on the aromatic nucleus with at least a halogen atom or a hydroxy, nitro, amino, cyano, carboxy, carboxamido, alkoxycarbonyl, lower alkyl, lower alkoxy or trifluoromethyl group; a nicotinyl group; an isonicotinyl group; a picolyl group; a furfuryl group; a 5-methyl-furfuryl group; a 2- or 3-thenyl group; a 5-methyl-2- or 3-thenyl group; or a 5-chloro-2-thenyl group;R.sup.2 represents hydrogen or a lower alkyl radical; andR.sup.3 and R.sup.4 represent each hydrogen, a halogen atom or a hydroxy, lower alkyl or lower alkoxy group,And their addition salts with inorganic or organic acids.Said new compounds have typically a therapeutically useful sedative and blood-platelet aggregation inhibiting activity.

Abstract: This invention relates to thieno[3,2-c]pyridine derivatives having the formula: ##STR1## in which: R.sub.1 represents an alkyl radical having 1-6 carbon atoms;R.sub.2 represents a radical selected from hydrogen and an acyl group;R.sub.3 represents a radical selected from hydrogen; an acyl group; an alkoxycarbonyl group; a phenyl group; a phenyl group substituted with at least a substitutent selected with at least a substituent selected from halogen, hydroxy, nitro, amino, cyano, carboxy, alkoxycarbonyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy; a phenoxy group; a phenoxy group substituted with at least a substituent selected from halogen, hydroxy, nitro, amino, cyano, carboxy, alkoxycarbonyl, C.sub.1-6 alkyl, and C.sub.1-6 alkoxy; and a trifluoromethyl group;R.sub.4 represents hydrogen, an acyl group, an alkoxy carbonyl group, or a phenyl or phenoxy group optionally substituted with at least a halogen atom or a hydroxy, nitro, amino, cyano, carboxy, alkoxycarbonyl, C.sub.1-6 alkyl, C.sub.

Abstract: This invention relates to pyridine derivatives of the formulae: ##STR1## in which R.sup.1 is hydrogen, lower alkyl, aralkyl optionally substituted on the aromatic nucleus with at least a halogen atom or a hydroxy, nitro, amino, cyano, carboxy, alkoxycarbonyl, lower alkyl, lower alkoxy or trifluoromethyl group; R.sup.2 is hydrogen or lower alkyl; and R.sup.3 is hydrogen or at least a substituent selected from a halogen atom, a hydroxy, lower alkyl and lower alkoxy group, and their pharmaceutically acceptable inorganic or organic acid addition salts.Said compounds have particularly an anti-inflammatory and blood-platelet aggregation inhibiting activity.